GSK Q3 revenue £8.89B beats estimate, adj EPS 54.6p; guides 2026 core EPS +7% to +9%

GSK reported Q3 2026 revenue of £8.89B, beating the £8.86B estimate, with adjusted EPS of 54.6p versus 50.3p expected. Shingrix revenue of £780M and Arexvy revenue of £195M missed estimates, and the company sees 2026 core EPS growth of +7% to +9%, at the lower half of its range. GSK affirmed FY2026 adjusted EPS guidance of $4.90-$5.00 and sales guidance of $44.754B, and targets FY2031 revenue above $53.2B.

Detected & updated continuously · Source: Nebula